openPR Logo
Press release

Nonalcoholic Steatohepatitis (NASH) Market is Determined to Cross US$ 20.0 Billion By 2025

03-26-2018 02:21 PM CET | Health & Medicine

Press release from: (MRE) Report

Nonalcoholic Steatohepatitis (NASH) Market

Nonalcoholic Steatohepatitis (NASH) Market

New York, March 26, 2018:

Nonalcoholic Steatohepatitis (NASH) Market 2018

Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025.

The scope of the report includes a detailed study of global and regional markets for various types of Non alcoholic steatohepatitis with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market.

The Nonalcoholic Steatohepatitis market is segmented on the lines of its Therapeutics such as GFT505, Obeticholic Acid (INT-747) Simtuzumab and Liraglutide (Victoza)Vitamin EPioglitazonePlacebo. The Nonalcoholic Steatohepatitis market geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

You Can Find Full Report: https://www.marketresearchengine.com/reportdetails/non-alcoholic-steatohepatitis-nash-market

Nonalcoholic Steatohepatitis market is segmented into therapeutic types and geography.

BY THERAPEUTICS
GFT505
Obeticholic Acid (INT-747)
Simtuzumab and Liraglutide (Victoza)
Pioglitazone
Placebo
Vitamin E

BY GEOGRAPHY
North America
Europe
Asia-Pacific
LAMEA

This report provides:
1) An overview of the global market for Non alcoholic Steatohepatitis and related technologies.
2) Analyses of global market trends and projections of compound annual growth rates (CAGRs) through 2025.
3) Identifications of new market opportunities and targeted promotional plans for Non alcoholic steatohepatitis market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.

The major driving factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:

1. There is a great increase in the cycles of the clinical trials with increased success rates. Hence there are increased chances of getting a commercial approval by 2017.

The restraining factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:

1. The unexplained and complex physiological structure.
2. Inefficient diagnostics technology which lengthen the commercialization of NASH therapeutics.

Request Sample Report: https://www.marketresearchengine.com/reportdetails/non-alcoholic-steatohepatitis-nash-market

Table of Contents
1. INTRODUCTION
2. Assumptions and Research Methodology
3. Executive Summary: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market
4. Market Overview
5. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Marker Type
6. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By End User
7. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Region
8. North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
9. Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
10. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
11. Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
12. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
13. Competition Landscape
13.1. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market – Competition Matrix (By Tier and Size of companies) (2015)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.2.1. BioPredictive S.A.S
13.2.2. One Way Liver S.L.
13.2.3. Genfit SA
13.2.4. Quest Diagnostics Incorporated
13.2.5. Prometheus Laboratories Inc. (Part of Nestle Health Sciences)
13.2.6. Siemens Healthcare Private Ltd. (now Siemens Healthineers)
13.2.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
13.2.8. Exalenz Biosciences Ltd.

About Us

Market Research Engine (MRE) is a next-generation provider of syndicated research, customized research, and consulting services. MRE’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each Market Research Engine’s research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Media Contact

Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Country: United States
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Market is Determined to Cross US$ 20.0 Billion By 2025 here

News-ID: 992545 • Views:

More Releases from (MRE) Report

Weight Management Market is Expected To Be Worth US$ 442 Billion By 2025
Weight Management Market is Expected To Be Worth US$ 442 Billion By 2025
New York, March 26, 2018: Weight Management Market 2018 The Global Weight Management Market is expected to exceed more than US$ 442.0 Billion by 2025 at a CAGR of 8.0% in the given forecast period. The scope of the report includes a detailed study of global and regional markets on Global Weight Management Market with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed
Home Healthcare Market is Expected To Be Worth US$ 300 Billion By 2022
Home Healthcare Market is Expected To Be Worth US$ 300 Billion By 2022
New York, March 26, 2018: Home Healthcare Market 2018 The Global Home Healthcare Market is expected to exceed more than US$ 300.7 Billion by 2022 at a CAGR of 7.4% in the given forecast period. The scope of the report includes a detailed study of global and regional markets on Global Home Healthcare Market with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed
Healthcare 3D Printing Market is Forecast to Cross US$ 4 Billion By 2022
Healthcare 3D Printing Market is Forecast to Cross US$ 4 Billion By 2022
New York, March 26, 2018: Healthcare 3D Printing Market 2018 The Global Healthcare 3D Printing Market is expected to exceed more than US$ 4 Billion by 2022 at a CAGR of 21.0% in the given forecast period. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include 3D Systems, Arcam AB, Renishaw PLC., EoS
Tumor Ablation Market is Projected to Reach US$ 650 Million By 2022
Tumor Ablation Market is Projected to Reach US$ 650 Million By 2022
New York, March 26, 2018: Tumor Ablation Market 2018 The Global Tumor Ablation Market is expected to exceed more than US$ 650 Million by 2022 at a CAGR of 12.0% in the given forecast period. The scope of the report includes a detailed study of global and regional markets for Global Tumor Ablation Market with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed

All 5 Releases


More Releases for Steatohepatitis

Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date. The NASH
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $2.67 billion In 2028
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance. NASH
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028 The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver. Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely